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Objectives: We aimed to assess the symptom burden and health related quality of 
life in patients with idiopathic lung fibrosis. MethOds: Patients have been consec-
utively enrolled in an ongoing prospective non-interventional registry in Germany, 
investigating clinical characteristics, clinical management practices and quality of 
life. IPF diagnoses were in agreement with the international IPF guideline published 
in 2011. Clinical parameters and treatment practice were recorded by the physi-
cian. Patients filled out the EQ-5D-5L, St George’s Respiratory Questionnaire (SGRQ), 
WHO-5 and the UCSD shortness of breath (SOB) scale. The time trade off (TTO) score 
was calculated for the EQ-5D. Results: To date (04 June 2014), 421 patients with IPF 
have been enrolled in the registry (mean age 68.6±9.5; 77% male). The mean six-min-
ute walk distance was 271±200, mean % of predicted forced vital capacity was 72±20 
and the mean % predicted DLCO was 35±16. Patients were treated with oral steroids 
(22.1%, as monotherapy in 7.1%); N-acetylcysteine (34.8%), pirfenidone (47.2%), and 
long-term O2 therapy (34.4%). The physician rated the disease in 35.6% as stable, 
in 31.1% as slowly progressing and in 11.9% as rapidly progressing. One in four 
patients described their current state of health as at least good, and every fifth as 
poor. The mean EQ-5D TTO score was 0.8±0.2. 45% of the patients showed depressive 
symptoms based on the WHO-5. The mean SGRQ sum score was 47.7±20.1 describing 
difficulties with breathing in the previous 3 months. Higher EQ-5D TTO scores were 
significantly associated with a lower number of comorbid diseases (r= -0.31), higher 
6-minute walk distance (r= 0.20), higher FVC % pred (r= 0.27), less depression (r= 0.66) 
and lower SGRQ scores (r= -0.72). cOnclusiOns: The IPF patients in this large reg-
istry had a more severe disease, a higher symptom burden and more compromised 
quality of life compared to recent randomised controlled trials.
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Objectives: The Nighttime Symptoms of COPD Instrument (NiSCI) and Early 
Morning Symptoms of COPD Instrument (EMSCI) were developed to support treat-
ment benefit endpoints in global clinical trials. Translations that were conceptually 
equivalent to the English source version and easily understood by the target country 
populations were required. The purpose of this study was to translate and assess 
conceptual equivalence of the NiSCI and EMSCI for use in 14 countries: Austria, 
Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, The 
Netherlands, Poland, South Africa, Spain, and United Kingdom. MethOds: The 
NiSCI and EMSCI were translated following ISPOR guidelines for linguistic valida-
tion of PRO measures (Wild et al., 2005) using the universal approach discussed in 
the second Task Force Report (Wild et al., 2009). The universal English, Spanish and 
French versions were previously translated (Eremenco et al., 2012). For the remain-
ing languages, two forward translations by native translators, reconciliation of the 
forwards, one back-translation by an English-speaker fluent in the target language, 
and final reconciliation by a native speaking language coordinator were conducted 
for both measures. Harmonization was performed to ensure conceptual equiva-
lence across languages. Interviews were conducted with five native-speaking COPD 
patients for each language/country combination. Interview data were analyzed to 
assess linguistic and cultural validity in each language and confirm conceptual 
equivalence. Results: Mean age of the sample (N= 80) was 60 years (range 41-83) 
and 54% were male. The translations were well understood and considered relevant, 
with patients raising only minor issues during interviews. Changes were made to the 
universal French (chest congestion), Hungarian (wheezing, chest congestion), Italian 
(chest congestion, moderately), and Lithuanian (instructions, wheezing, shortness 
of breath, experienced) following the patient interviews. cOnclusiOns: All trans-
lated versions of the NiSCI and EMSCI in this study were found to be conceptually 
equivalent and acceptable for use in the 14 countries evaluated.
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Objectives: Usability testing of electronic Patient-Reported Outcomes (ePRO) 
instruments is typically conducted during instrument development, in the lan-
guage/country of origin. It has been suggested that usability testing also be per-
formed during the translation process. It is unclear whether this additional step 
is necessary. In this study, usability testing was conducted as part of the linguis-
tic validation process in Simplified Chinese (China), German (Germany), French 
(France), Russian (Russia), and Spanish (Universal, tested in Chile, Spain, and US) 
for the Exacerbations of Chronic obstructive pulmonary disease Tool (EXACT), an 
e-PRO developed and tested in English (US). MethOds: The translation process 
followed ISPOR guidelines (Wild et al., 2005). Cognitive interviews were conducted 
with 2-3 native-speaking COPD respondents per language/country combination 
in 2008. Subjects completed the EXACT in paper-pen screenshot format and were 
interviewed for translation validation. Subsequently they were instructed to use a 
PDA (Tungsten E2; CRF, Inc.) to complete the first 5 EXACT items and were inter-
viewed regarding device usability. Interviewers rated subjects’ ability to use the 
device. Results: Subjects (N= 20) were 45-84 years, 60% male, and 60% with second-
ary education or less. Most (n= 18) had not used a PDA previously; all (n= 20) reported 
oids (76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); 
oral-corticosteroids (1.3%). BDI: grade 2. Primary outcome: RCT cohorts: there was 
no difference between control and intervention A and there were statistically 
significative differences between intervention B versus control (p< 0.0001), NNT= 3.22 
(IC95%, 2.27-5.88) and versus intervention A, NNT= 4.16 (IC95%, 2.63-10). In the PPS 
cohorts: there was a difference (p< 0.0001) between intervention B versus interven-
tion A, NNT= 3.22 (IC95%, 2.32-5.55). The preferences enhanced a 6.7% the correct 
inhalation technique. cOnclusiOns: The performance of a correct inhalation 
Technique improves with monitor training. The patients´ preferences enhance the 
efficacy of intervention.
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Objectives: To test the efficacy of two educational interventions to improve the 
inhalation techniques per device in patients with COPD and the influence of patient´ 
preference. MethOds: Design: Multicenter patients´ preference trial or compre-
hensive cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a 
difference between groups of 25%, 80% statistical power, 95% confidence level, 40% 
expected losses), with inhaled treatment, written consent. Non-probabilistic con-
secutive sampling. Allocation: Patients without strong preferences for a treatment 
are randomised: RCT group (block randomization), and those with strong prefer-
ences are given their choice: PPS group. Variables: Primary outcomes: Performance of 
correct inhalation technique. Independent variables: sex, age, Baseline dyspnea index 
(BDI), Functional status (forced spirometry). Interventions: Interv-A: Written infor-
mation. A leaflet with correct inhalation technique. Interv-B: Interv-A + individual 
training (by instructors). Follow-up: 3 month, visits: baseline (V0), 1 month (V1), 
3 month (V2). Statiscal analysis: Mean, frequency, 95% confidence interval. Intention 
to treat analysis. Results: Males (91.4%), mean age 69.8 years (CI95%, 69.00-70.59); 
FEV1 (mean)= 55.91% (IC95%, 53.62-58.2), mixed respiratory pattern (65.9%). Severity 
stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. BDI: grade 2. Devices use: 67.3% 
Handihaler (Hd), 54.8% Turbuhaler (Th), 31.8% Accuhaler (Acc), 26.9% pMDI. Correct 
Inhalation technique: hd: RCT-control: 11.7% V0,10% (V2); RCT-intervA: 10.9%, 17.5%; 
RCT-IntervB: 7.4%, 62.3% p< 0.0001. Th: RCT-control: 22% V0, 16.7% (V2); RCT-intervA: 
8.7%, 24.4%; RCT-IntervB: 7.5 %, 57.5% p< 0.0001. acc: RCT-control: 16.1% V0, 25% (V2); 
RCT-intervA: 17.9%, 23.1%; RCT-IntervB: 11.5%, 74.1% p< 0.0001. pmdi: RCT-control: 
6.9% V0, 3.6% (V2); RCT-intervA: 12.5%, 19%; RCT-IntervB: 8.3%, 34.6% p= 0.025. 
There were statistically differences for all devices only in the intervention B arms 
(p< 0.0001). The preferences enhanced 1% for Handihaler, 12.7% for Accuhaler, 4.6% 
for Turbuhaler, 15.4% for pMDI the correct inhalation technique. cOnclusiOns: 
The performance of a correct inhalation technique improves with monitor training 
for all devices. The patients´ preferences enhance the efficacy.
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Objectives: To identify characteristics of dry powder inhalers (DPIs) considered 
important by asthma and chronic obstructive pulmonary disease (COPD) patients, 
in order to select attributes and attribute-levels for a discrete choice experi-
ment. MethOds: Qualitative data was collected from a literature review performed 
to determine which inhaler attributes impact inhaler satisfaction and adherence 
among asthma and COPD patients using DPIs. Focus groups with asthma and COPD 
patients were conducted in France, with patients asked to cite and rate important 
features of their inhaler. Qualitative analysis of the transcripts was performed 
following International Society For Pharmacoeconomics and Outcomes Research 
(ISPOR) guidelines. Results: Results of the literature review revealed no overall 
consensus on the importance of different inhaler attributes in relation to inhaler 
satisfaction and adherence across studies. The most frequently reported attributes 
were: overall ease-of-use, low inspiratory flow requirements, presence of a dosing 
feedback mechanism, ergonomics of the inhaler mouthpiece, ease with which the 
device can be kept hygienic and the ease with which the medicinal dose can be pre-
pared. Four discussion groups were held, with thirty patients participating. Overall, 
the degree to which the inhaler can optimise treatment convenience appeared 
to be the most important attribute to patients. In agreement with results of the 
literature review, patients also rated the following inhaler attributes as being impor-
tant: size of the dose counter, ability to keep the mouthpiece hygienic, ergonomics 
of the inhaler mouthpiece, presence of a dosing feedback mechanism, ease with 
which a dose can be prepared, low inspiratory flow requirements. cOnclusiOns: 
Results of this study provide an insight inhaler attributes most valued by asthma 
and COPD patients. Patients described their ideal inhaler to be small, with an ergo-
nomic mouthpiece and an easy to use dose preparation mechanism, and providing 
enough medicine for at least a month of treatment.
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factors, potentially related with the mentioned respiratory diseases prevalence, 
as age, sex, smoking habits were analyzed. Four groups were compared: 1) asthma 
patients, 2) COPD patients, 3) patients with other chronic conditions, and 4) global 
Spanish population. Results: Data from 21,007 adults was recorded. Prevalence 
of asthma was slightly above COPD (5.4% vs 4.7%), and 47.2% were suffering from 
chronic diseases. Asthma patients were younger than those with COPD (51y vs 
61y, as an average, respectively). Concerning EQ-5D results, the dimensions mainly 
affected either in COPD or asthma were, respectively, pain/discomfort (53.7% / 
38.7%), mobility (42% / 27.4%), usual activities (34.4% / 21.8%), and depression/anxi-
ety (32.4% / 25.4%). Based on the EQ-5D questionnaire, the QALYs calculation were 
0.75 for COPD and 0.90 for asthma patients, the latter results were similar to the 
other chronic conditions and to the global population. Health resources in COPD 
patients were significantly higher than in the other 3 groups analyzed, considering 
office visits (GPs/Specialists), hospitalization and emergency unit visits during the 
last year. cOnclusiOns: Patients diagnosed with asthma have a similar HRQOL 
compared to the rest of the population, but COPD patients have it worse. COPD 
is also associated with a higher health resources consumption, which implies a 
relevant impact on the Spanish National Health System.
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Objectives: As young students are more prone to smoking and associated dan-
gers it affects their health related quality of life (HRQoL). This study was done to 
assess the HRQoL and other associated factors affecting HRQoL among smokers 
and non-smokers who are students. MethOds: In this exploratory study a pilot 
tested questionnaire was used to collect information regarding young students, 
demographics, BMI, food habits, alcohol consumption, family history of smoking 
as well as family history of diseases. For health related quality of life measurement 
both descriptive and visual analogue score (VAS) of EQ 5D 5L questionnaire ware 
used. The data collected was analyzed using SPSS 16.0.0. The test of significance 
was done by using Chi Square test for checking the associated habits and Mann 
Whitney U test is done to check the significance of association between HRQoL 
and smoking and other associated habits. Results: Total 126 students were 
included in the study. The age was 22.9±2.17 (Mean±SD) and BMI was 22.03±4.27 
(Mean±SD) and all of them were residing in an University town. 63 % of the stu-
dents were non-vegetarians and 44.8% were consuming alcohol at least once 
in a month. The mean EQ 5D visual analogue score of the studied population 
was found to be 83.3±11.5 (Mean±SD). The Chi square test showed the associa-
tion between smoking with family history of smoking, alcohol consumption and 
soft drinks consumption (p< 0.001, 0.001 and 0.05 respectively). Mann Whitney 
U test showed as significant difference in the VAS scores among smokers and 
non-smokers (p< 0.05). cOnclusiOns: Health Related Quality of Life is severely 
compromised by smoking, hence there is an urgent need to create awareness 
among young students.
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Objectives: The aim of this study is to evaluate the health related quality of life 
(HRQoL) and health care utilization in primary care (PC) patients with asthma 
treated with beclomethasone/formoterol. MethOds: This study analyzed the 
HRQoL and health care utilization from a cohort of 65 patients over 6 months. 
Inclusion criteria were patients aged 18 years and older with moderate/severe per-
sistent asthma (GINA criteria) treated with beclomethasone/formoterol at least 1-3 
months before the inclusion in the study. Sociodemographic variables such as age, 
sex, duration of disease, severity of asthma, concomitant pathology were evalu-
ated. The evaluation of the HRQoL were measured with the Asthma Quality of Life 
Questionnaire (AQLQ), and two generic questionnaires, EuroQol-5D and SF-36. The 
evaluation of the health care utilization included visits to PC, visits of care nursing 
and visits to accident and emergency (A&E) department and admissions. Statistical 
analysis: average ± standard deviation (SD); frequency and proportions. Inferential 
statistics in terms of average HRQoL and health care utilization were calculated 
using T-Student, Chi-square and ANOVA. Results: Average patients were female 
(60%), aged 49 years old (SD 2.16) with disease duration of 92 months (SD 18.34). 
The average health care utilization was: 3.43 (SD 0.35) visits to PC and 1.42 (SD 
0.29) visits to nursing; analytical: 0.63 (SD 0.09); chest x-ray: 0.38 (± 0.08); ECG 0.32 
(SD 0.08). The average of exacerbations without hospital admission was 1.09 (SD 
0.19) and the A&E department visits of PC related with asthma was 0.43 (SD 0.11). 
Statistically significant differences (p < 0.05) and clinically significant between the 
beginning and end of the study on all forms of quality of life measured in these 
patients were found measured with AQLQ, EuroQol-5D and SF36. cOnclusiOns: 
Beclomethasone/formoterol improved HRQOL in patients with asthma representing 
a good cost/utility relationship.
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Objectives: The aim of this study was to assess impairment in health-related 
quality of life (HRQoL) of pulmonary tuberculosis (PTB) patients in Pakistan. This 
study also evaluated utility of various socio-demographic and clinical factors that 
it was easy to use, the screens were easy to read, and that they could sign on and 
move through the questions with no difficulty. Subjects from the Spanish-speaking 
countries had the lowest reported difficulty turning the device on, with higher 
levels of difficulty observed by the interviewers in China, who reported “somewhat” 
for two of the three respondents. Interviewers observed that the majority (n= 15) 
could “easily” or “very easily” use the device. cOnclusiOns: Given the consistent 
ease-of-use findings in these diverse, device naïve subjects across 7 countries and 
the emphasis on subject training in clinical trials, it was determined that usability 
testing with future translations was unnecessary.
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Objectives: The Nighttime Symptoms of COPD Instrument (NiSCI), developed 
through qualitative research with patients, includes six symptom items: cough-
ing, wheezing, shortness of breath, difficulty bringing up phlegm, chest conges-
tion, and tightness in the chest. A symptom severity score is computed based on 
these items. In situations where patient burden is a major consideration, a smaller 
set of items may be preferable. Clinicians identified coughing, wheezing, short-
ness of breath, and difficulty bringing up phlegm as the most relevant for COPD 
patients. Exploratory psychometric analyses were conducted for the symptom sum-
mary score based on these four items compared with all six items. MethOds: 
Psychometric properties of the four-item versus six-item symptom summary scores 
were examined using phase 3 clinical trial data from a random split-half sample. 
Symptom summary scores were tested for: internal consistency using Cronbach’s 
Alpha; test-retest reliability using Intraclass Correlation Coefficients (ICC) and 
Concordance Correlation Coefficients (CCC); convergent validity using Spearman 
Rank Order Correlation Coefficients; and known-groups validity using ANOVA and 
Scheffe’s test for pair-wise comparisons. Results: Patients (n= 832) were aged 40–93 
years (mean 63.78 ±-9.07 [SD]) and 51% were male. Both scores were internally 
consistent and valid. Cronbach’s alpha was slightly higher for the six-item symp-
tom summary (0.85) versus the four-item symptom summary (0.78). ICC and CCC 
scores were 0.85 for the six-item and 0.84 for the four-item symptom summary 
scores. Likewise, construct validity and known-groups validity were similar for both 
scores (p> 0.05). cOnclusiOns: The NiSCI symptom summary score based on four 
items has similar psychometric properties to the six-item symptom summary score. 
Both scores have measurement properties suitable for use in clinical trials. Further 
work will test the psychometric properties of the instrument administered with 
four items.
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Objectives: Idiopathic pulmonary fibrosis (IPF) is a progressive disease charac-
terized by declining lung function, leading to debilitating limitations on activity 
which may negatively impact HRQOL. However, HRQOL data in this population 
are limited. The primary objective was to evaluate HRQOL in IPF using measures 
from the Patient Reported Outcomes Measurement Information System (PROMIS). 
The secondary objective was to examine the association between key symptoms 
and HRQOL. MethOds: Individuals with IPF were recruited via patient advocacy 
organizations to complete an online survey consisting of PROMIS-29 health pro-
file, PROMIS-Dyspnea, dyspnea measured by Modified Medical Research Council 
Dyspnea Scale (MMRC), self-reported cough, and cough subscale of the ATAQ 
(A Tool to Assess Quality of life)-IPF. PROMIS-29 scores have mean= 50, SD= 10 in the 
US general population; PROMIS-Dyspnea scores are referenced to a chronic obstruc-
tive pulmonary disease (COPD) sample. Results: The 275 survey participants 
showed worse mean PROMIS-29 scores than the general population in all meas-
ured domains (mean value: anxiety= 63.9; depression= 61.9; fatigue= 60.1; pain= 62.6; 
sleep disturbance= 55.8; physical function= 36.2; social role= 42.2). Dyspnea severity 
was associated with worse mean PROMIS-29 scores (all p< 0.05). PROMIS-Dyspnea 
(mean= 58.7) and Functional Limitations Due to Dyspnea (mean= 58.4) scores were 
worse than the COPD reference population. Cough severity was associated with 
worse HRQOL measured by ATAQ-IPF. Reliability of PROMIS-29 scores exceeded 0.65 
and were moderately correlated with measures of similar constructs. A limitation 
of the study is that data drawn from a sample from advocacy organizations might 
not be generalizable to the entire IPF population. cOnclusiOns: Patients with IPF 
report substantial deficits in HRQOL, particularly with respect to physical function, 
anxiety, pain, depression and fatigue. Patients suffering from dyspnea and cough 
had poorer HRQOL. These deficits should be monitored in clinical practice and 
evaluated in investigational trials aiming to improve the HRQOL of IPF patients.
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Objectives: To analyze the impact that asthma and chronic obstructive pulmo-
nary disease (COPD) have on patients Health Related Quality of Life (HRQOL) and 
on health resources consumed by the Spanish Health System. MethOds: Data 
obtained from the last Spanish National Health Survey (SNSHS) 2011-12, on adult 
population (> 15y), identifying patients with a diagnostic of asthma or COPD. 
Descriptive statistic analysis was carried out, specially focused on self-reported 
HRQOL (EQ-5D-5L) and health resources utilization. The EQ-5D results were trans-
lated into QALYs, with the social tariffs validated in Spain. Other demographic 
